New drug slashes bad cholesterol without statins in chinese study

NCT ID NCT05888103

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 19, 2026 · Last updated May 16, 2026 · Updated 19 times

Summary

This study tested a drug called inclisiran in 207 Chinese adults with high LDL (bad) cholesterol who were not taking other cholesterol medicines. Participants received either inclisiran or a placebo for 6 months, followed by 6 months where everyone got the drug. The goal was to see how well inclisiran lowers cholesterol on its own. Results showed it effectively reduced LDL cholesterol levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Fuzhou, Fujian, 350025, China
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Zhongshan, Guangdong, 528403, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Changsha, Hunan, 410003, China
Novartis Investigative Site

Changsha, Hunan, 410011, China
Novartis Investigative Site

Hohhot, Inner Mongolia, 010017, China
Novartis Investigative Site

Changzhou, Jiangsu, 213004, China
Novartis Investigative Site

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site

Nanchang, Jiangxi, 330009, China
Novartis Investigative Site

Jinzhou, Liaoning, 121001, China
Novartis Investigative Site

Linyi, Shandong, 276000, China
Novartis Investigative Site

Taiyuan, Shanxi, 030002, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Tianjin, Tianjin Municipality, 300121, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Beijing, 100029, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Beijing, 101200, China
Novartis Investigative Site

Jinan, 250012, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Shanghai, 200120, China
Novartis Investigative Site

Tianjin, 300052, China
Novartis Investigative Site

Tianjin, 300140, China

Conditions

Explore the condition pages connected to this study.

PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA